Cellphire, Inc., the global leader in long-term stabilization and storage of platelets, announced today that Heather Pidcoke, MD, MSCI, Ph.D., has joined the company as Chief Medical Officer. Dr. Pidcoke’s translational research interests include trauma critical care and novel transfusion products aimed at improving the resuscitation of massively bleeding patients.
Prior to joining Cellphire, Dr. Pidcoke was Director, Global Translational Affairs at Terumo BCT where she was the Principal Investigator for four major product development efforts. Previously, she served as the Deputy Task Area Manager and Research Physiologist in the Coagulation and Blood Research program (CBR) at the U.S. Army Institute of Surgical Research (USAISR) and as Adjunct Professor in the Department of Surgery at the University of Texas, Health Science Center, San Antonio. Dr. Pidcoke was awarded a U.S. Army Commander’s Award for Civilian Service in recognition of her contributions in advancing medical research for military personnel, and the Presidential Early Career Award for Scientists and Engineers.
She received a Doctor of Medicine degree from the Keck School of Medicine of the University of Southern California and a Ph.D. (Physiology) from the Graduate School of Biomedical Sciences at the University of Texas Health Science Center.
“We are very excited to have Dr. Pidcoke join Cellphire”, said G. Michael Fitzpatrick, President and Director of R&D. “Her experience and expertise will allow us to move Thrombosomes and other developmental projects into the physician’s hands sooner and revolutionize blood support in the 21st century.”
About Cellphire
Cellphire, Inc. is a biotechnology company developing next-generation therapeutics. The company is applying its proprietary cell stabilization technology to all cell types, including platelets, to develop lifesaving products. Its lead product is Thrombosomes®, a freeze-dried hemostatic derived from human platelets. Cellphire’s technology has potential applications across a wide range of medical applications from trauma to wound care, imaging, targeted drug delivery, and regenerative medicine. For more information, visit www.cellphire.com.
Contacts:
Media
Sharon Burns
Director, Communications
sburns@cellphire.com
Investor Relations
Tom Dann
Chief Investment Officer
tdann@cellphire.com